Acadia Pharmaceuticals (ACAD -10.2%) crashes after disclosing it's discontinuing development for...

|By:, SA News Editor

Acadia Pharmaceuticals (ACAD -10.2%) crashes after disclosing it's discontinuing development for its AM-831 schizophrenia drug after it failed to "meet pre-determined criteria for further development in Phase I testing." AM-831 was being developed in partnership with Japan's Meiji Seika Pharma.